{"document_type": "article", "byline": [], "news_desk": "Letters", "slideshow_credits": null, "abstract": null, "multimedia": [], "headline": {"kicker": "Letter", "content_kicker": "Letter", "print_headline": "Cancer Drug Dosing", "main": "Cancer Drug Dosing"}, "print_page": null, "keywords": [{"value": "Drugs (Pharmaceuticals)", "is_major": "N", "rank": "1", "name": "subject"}, {"value": "Cancer", "is_major": "N", "rank": "2", "name": "subject"}], "snippet": "The Pharmaceutical Research and Manufacturers of America discusses the regulatory barriers to getting product modifications to market.", "source": "The New York Times", "lead_paragraph": "The Pharmaceutical Research and Manufacturers of America discusses the regulatory barriers to getting product modifications to market.", "word_count": "156", "pub_date": "2016-03-12T00:00:00Z", "subsection_name": null, "blog": [], "type_of_material": "Letter", "section_name": "Opinion", "web_url": "http://www.nytimes.com/2016/03/12/opinion/cancer-drug-dosing.html", "_id": "56e3375438f0d81b768a681b"}